Scientific Advisor Endocrinology

Dr. Anastassios Pittas, MD, MS

Dr. Pittas is the Chief of the Division of Endocrinology, Diabetes, and Metabolism; Co-Director, Diabetes and Lipid Center, Professor of Medicine at Tufts University School of Medicine and Adjunct Professor of Nutrition and Policy at Tufts University Friedman School of Nutrition, Science and Policy. Dr. Pittas serves as the Associate Director of the Endocrinology Fellowship Program and co-Director of the Diabetes Clinic. From 2000 to 2008, he served as the Director of the Endocrine Pathophysiology course at Tufts University School of Medicine. Dr. Pittas holds a Bachelor of Science in Biology from MIT, a Master of Science in Clinical Research from the Sackler School of Biomedical Sciences at Tufts University, an MD from the Weill Medical College of Cornell University, completed his Internal Medicine Residences at the New York Presbyterian Hospital, and a Fellowship in Endocrinology, Diabetes, and Metabolism at the Tufts Medical Center.

Scientific Advisor Rheumatology

Dr. Timothy McAlindon, MD, MPH

Dr. McAlindon is the Program Director of Musculoskeletal Research at the University of Massachusetts Medical School and formerly the Chief of the Division of Rheumatology at the Tufts Medical Center and Professor of Medicine at Tufts University School of Medicine. Dr. McAlindon is a renowned authority in Rheumatology, having led the American College of Rheumatology (ACR) Rheumatoid Arthritis (RA) Clinical Treatment Guideline Literature Review Team and chaired the Osteoarthritis Research Society International (OARSI) Treatment Guideline Development Committee. Dr. McAlindon received his Doctorate in Medicine and Bachelor of Medicine from the University of Southampton Medical School, his MPH from Boston University School of Public Health, and completed medical training at the Bristol Royal Infirmary, and St. Thomas' Hospital in London in the UK.

Scientific Advisor Endocrinology

Dr. Kai Zou, PhD, MS, BS

Dr. Kai Zou is a Fellow of the American College of Sports Medicine and Associate Professor in the Department of Exercise and Health Sciences at the University of Massachusetts Boston. He holds a Ph.D. in Kinesiology from the University of Illinois at Urbana-Champaign with Postdoctoral training at the East Carolina Diabetes and Obesity Institute at East Carolina University. Currently, Dr. Zou leads the Muscle Metabolism and Physiology Laboratory focusing on molecular mechanisms underlying the development of insulin resistance and type 2 diabetes, and how exercise improves glucose metabolism and insulin sensitivity in diabetes. Dr. Zou led several research projects funded by the National Institutes of Health, National Science Foundation, and the American Heart Association having generated high-impact publications in renowned journals such as Molecular Metabolism, International Journal of Obesity, Medicine & Science in Sports & Exercise, Journal of Applied Physiology, American Journal of Physiology, Stem Cell Research, and Obesity. Additionally, Dr. Zou serves on the Editorial Board for the Journal of Applied Physiology, American Journal of Physiology – Cell Physiology, and International Journal of Sports Medicine.

Corporate Advisor

Dr. Charles Sherwood, PhD

Dr. Sherwood is the Founder of Sherwood Ventures, a biotech-focused early stage Venture Capital firm, and formerly the President and CEO of Anika Therapeutics, a global public-market rheumatology-focused specialty pharmaceuticals company. Prior to Anika, Dr. Sherwood held roles of increasing responsibilities at companies including J&J and Chiron. Holding a Bachelor of Science in Chemical Engineering from Cornell and a Ph.D. in Polymer Science and Engineering from the University of Massachusetts, Boston, Dr. Sherwood brings over five decades of rheumatology and osteoarthritis experience to Remedium Bio. Dr. Sherwood led the development, industrialization, clinical trials, and commercial launch of a number of currently market-leading palliative OA therapies including Monovisc®, Orthovisc®, and Cingal®; as well as a first-in-class cell therapy HyalograftC® and EU-market leading single step focal cartilage lesion repair product Hyalofast®.

Scientific Advisor Rheumatology

Prof. Li Zeng, BA, MS, MA, PhD

Dr. Zeng is the Associate Professor of Immunology at the Graduate School of Biomedical Sciences at Tufts University and a renowned authority in Osteoarthritis research. Dr. Zeng holds an MA and PhD in Cell & Molecular Biophysics from Columbia University, an MS in Biochemistry from Tsinghua University, and a BA in Plant Physiology & Biochemistry from Beijing Agricultural University. Dr. Zeng manages a research laboratory at Tufts University conducting rheumatology research focused on the understanding of cartilage development in vertebrate embryos, molecular mechanisms involved in cell fate determination during cartilage formation and patterning, as well as cartilage-related defects, arthritis, and cartilage repair.

Scientific Advisor Rheumatology

Dr. Jeff Ellsworth, PhD

Dr. Ellsworth is a renowned authority on the FGF18 protein and its applications in the treatment of Osteoarthritis and Stroke, having led the R&D team that originally discovered FGF18’s ability to regenerate cartilage. Dr. Ellsworth holds a PhD in Pharmacology and Cell Biophysics from the University of Cincinnati College of Medicine and a Bachelor of Science in Chemistry from the Indiana University Bloomington. Upon completion of his dissertation defense, Dr. Ellsworth spent a number of years as a post-doctoral fellow at Stanford University School of Medicine researching lipoprotein receptors and lipid metabolism. Dr. Ellsworth has held roles of increasing responsibilities at CV Therapeutics, ZymoGenetics, Moderna, and Homology Medicines and is currently the CSO at the cardiac regeneration company Recardia Therapeutics, Inc.

Chairman of the board

Frank Luppino

Frank Luppino is the President and CEO of Remedium Bio, also serving as the Chairman of the Board of Directors. Prior to joining Remedium Frank's successful track record includes the development, industrialization, and commercial launch of a broad array of products including Cell Therapies for wound and cartilage repair, anti-inflammatory and analgesic Drug-Device combination products in orthopedics and aesthetic medical markets, as well as biologic macromolecules for the prevention of surgical adhesions.

Prior to joining Remedium, Frank served in a series of executive roles including as the CEO of Biosource CXO, Chief Operating Officer of Anika Therapeutics, Vice President of Operations at Bionostics, and various roles of increasing responsibility at Raytheon and Black & Veatch. Frank holds a Bachelor of Science from Lehigh University. 

Board member

Richard Hague

Richard is an accomplished life sciences executive and board member with extensive experience in the development and commercialization of innovative cell based therapies, drug-device combinations and medical devices. He is currently board chairman at Omeza, a pioneering wound care company. Most recently, as the President & CEO of PolarityTE, Richard led the company’s successful transition to a 351 BLA regulated pathway resulting in an accelerated Phase III IND approval for its cell therapy platform for skin regeneration and the sale of the company’s assets to private investors.

Before joining PolarityTE, Richard held executive roles with several leading healthcare companies, which included Genzyme and later Sanofi (post Sanofi's acquisition of Genzyme) where he was VP/General Manager of the company’s Cell Therapy and Regenerative Medicine Business Unit. While at Genzyme, he was involved in the launch of the first autologous cell therapies for cartilage repair and burns and the first HA injectable for the management of osteoarthritis pain. Richard’s broad experience includes raising capital, licensing and M&A transactions, and successful product launches via the CBER and CDRH regulatory pathways. Richard is a graduate of the University of Connecticut’s School of Business.

Board member

Harry Robb

Harry Robb is a venture capital professional specializing in biotech, pharmaceuticals, and the emerging longevity market, with a broad focus on deep-tech innovations. He currently serves as Principal at Lifespan Vision Ventures and Barron Venture Partners and holds board positions at several Lifespan portfolio companies. Previously, Harry was an Investment Manager at Longevity. Technology, a media and investment platform dedicated to the longevity sector, where he built a global network of institutional and private investors and led deal origination efforts. He holds an MSc in Applied Biosciences and Biotechnology from Imperial College London and a BSc in Biomedical Sciences from King's College London.

Board member

Alex Goraltchouk

Alex Goraltchouk is the Chief Technology Officer at Remedium Bio. Alex has extensive background developing and industrializing biologics, small molecules, as well as gene and cell therapy products at companies including Allergan, Regeneron, and Biogen. Prior to Remedium, Alex held several executive roles at public and private companies leading the development and industrialization of clinical and commercial products in the Endocrinology, Rheumatology, and Cardiology space.

Alex holds a Bachelor in Materials Engineering and Master in Chemical Engineering from the University of Toronto, an MBA and Master of Science in Finance from Indiana University, and a Master of Microbiology and Cell Sciences from the University of Florida. He is a Cornell Certified Six Sigma Black Belt, holds an MIT MicroMasters in Supply Chain Management, and a PMP certification from the Project Management Institute.